Kenacort Injection

📦 Każde zamówienie jest objęte naszą Reshipment Assurance Policy — jeśli Twoja przesyłka nie dotrze w ciągu 20 dni roboczych, wysyłamy ją ponownie.

Dlaczego warto zamawiać z MedsBase

Nasze leki generyczne pochodzą od producentów posiadających certyfikat WHO-GMP i są wysyłane na cały świat w dyskretnym, zwykłym opakowaniu — bez nazwy leku na zewnątrz przesyłki. Płatności kartami są kierowane przez regulowanego procesora (opis wyciągu zawiera nazwę regulowanego procesora płatności — nigdy “MedsBase” ani żadnej nazwy leku). Akceptujemy również kryptowaluty i przelewy bankowe SEPA. Każde zamówienie jest objęte naszą Reshipment Assurance Policy.

What Is Kenacort Injection?

Kenacort Injection is a depot suspension for intramuscular and intra-articular injection manufactured by Abbott Healthcare containing triamcinolone acetonide — a synthetic corticosteroid in the glucocorticoid class. Glucocorticoids are the most powerful broad-spectrum anti-inflammatory and immunosuppressive drugs available, with effects across almost every tissue and organ system.

Kenacort Injection is the original Indian-market injectable triamcinolone acetonide depot from Abbott Healthcare. The 10 mg/mL strength is used for small-joint intra-articular injection and intralesional dermatology (alopecia, scars). The 40 mg/mL strength is used for intramuscular depot, large-joint intra-articular (knee, shoulder) and high-dose intralesional treatment of keloid scars.

Triamcinolone 4 mg is approximately equivalent to prednisolone 5 mg (potency ratio ~5). The physiological daily cortisol output of a healthy adult is approximately 5–7.5 mg of prednisolone-equivalent — any dose above that is “supraphysiological” and begins to suppress the hypothalamic-pituitary-adrenal (HPA) axis.

Why a depot suspension? Triamcinolone acetonide is far less water-soluble than the sodium-phosphate or sodium-succinate esters used for IV steroids. Once injected, it forms microscopic crystals that dissolve over weeks, providing sustained low-dose glucocorticoid release without the daily-dosing burden of oral therapy. This is ideal for joint inflammation (where an injection inside the joint capsule keeps the drug locally concentrated), severe seasonal allergy (one IM injection covers most of the pollen season), and dermatology (localised intralesional injection of keloids, alopecia patches, hypertrophic scars).

How Does Kenacort Injection Work?

Triamcinolone enters cells, binds the intracellular glucocorticoid receptor, and the receptor-drug complex translocates to the nucleus where it alters transcription of hundreds of genes. The end result is a broad dampening of the inflammatory cascade:

• Suppresses pro-inflammatory cytokines (IL-1, IL-6, TNF-α, IFN-γ) and chemokines.
• Stabilises lysosomal membranes, reducing release of proteolytic enzymes into tissue.
• Inhibits phospholipase A₂ via lipocortin, cutting off the prostaglandin and leukotriene pathways upstream.
• Reduces capillary permeability and tissue oedema.
• Suppresses B- and T-lymphocyte function and circulating lymphocyte counts (relative lymphopenia).
• Reduces eosinophil and basophil activity, partially explaining the rapid effect in asthma, allergy and eosinophilic conditions.

Clinical onset (depot IM/IA): noticeable improvement within 24–48 hours for joint inflammation; peak effect at 7–14 days. Total duration of useful effect: 2–6 weeks (joint), 3–6 tygodni (IM depot for allergic rhinitis), 2–3 months (intralesional in keloid scars).

— wzmacnia normalną odpowiedź fizjologiczną, a nie wywołuje ją sztucznie.

Kenacort Injection is used wherever sustained local or systemic glucocorticoid effect is wanted from a single injection.

Intra-articular (IA) injection — into a joint

• Osteoarthritis flare of knee, shoulder, hip, ankle, small joints — typical effect 4–8 weeks
• Rheumatoid arthritis monoarticular flare — useful when only 1–2 joints are active
• Crystal arthropathies (gout, pseudogout) — selected cases after diagnostic aspiration
• Bursitis, tendinitis, plantar fasciitis, trigger finger, carpal tunnel syndrome (peri-articular)
• Frozen shoulder (adhesive capsulitis)

Intramuscular (IM) depot — gluteal injection

• Severe seasonal allergic rhinitis (hay fever) — controversial; one 40–80 mg IM depot can cover most of the pollen season but carries cumulative steroid burden equivalent to several weeks of oral prednisolone
• Severe atopic dermatitis or contact dermatitis flare — when topicals and a short oral course are insufficient
• Asthma exacerbation in patients who cannot take or tolerate oral steroids
• Acute exacerbation of inflammatory disease in patients with poor oral compliance

Intralesional injection — into the lesion

• Keloid and hypertrophic scars — 10–40 mg/mL injected directly into the scar, repeated every 3–6 weeks for several cycles
• Alopecia areata — 5–10 mg/mL injected into the patch, repeated every 4–6 weeks
• Łuszczyca plackowata — selected resistant lesions
• Discoid lupus, lichen planus, granuloma annulare, necrobiosis lipoidica

Kenacort Injection is otrzymuje, przechowuje, nie ma dostępu ani wglądu w dane osobowe przekazywane przez Ciebie dostawcy płatności. Proces weryfikacji odbywa się w całości na platformie dostawcy i podlega jego własnej polityce prywatności oraz standardom bezpieczeństwa. appropriate for: routine first-line management of osteoarthritis (lifestyle, weight, physiotherapy and NSAIDs first), septic arthritis (steroid is contraindicated until infection cleared), spinal injection (has been associated with rare but devastating cord infarction — best avoided in favour of soluble preparations), or any joint that has been injected within the past 3 months.

Kenacort Injection Dosage and How to Use

Kenacort Injection is supplied at 10 mg/mL and 40 mg/mL vials. Dose depends entirely on the indication and the route — this is a specialist or trained-clinician procedure, not for self-administration.

Typical adult doses by route and indication

How Kenacort Injection Is Administered

1. Aseptic technique throughout — skin prep with chlorhexidine or povidone-iodine, sterile gloves, single-use needles.
2. Shake the vial well immediately before drawing up — this is a suspension, not a solution; the active drug settles and must be re-dispersed.
3. Use a new needle to draw up and a fresh needle to inject — reduces skin-flora seeding into a joint.
4. For IA injection: confirm needle position (aspiration of synovial fluid or anatomical landmarks; ultrasound guidance increasingly preferred). Aspirate effusion first if present, then inject. Some clinicians mix triamcinolone with 1–2 mL of 1% lidocaine without epinephrine for immediate symptomatic relief.
5. For IM depot: use the dorsogluteal or ventrogluteal site, deep IM with 21G or 22G needle 1.5–2 inches long. Z-track technique reduces skin/subcutaneous leakage and the resulting fat-atrophy and depigmentation.
6. For intralesional injection: dilute appropriately, use 27G or 30G needle, inject into the dermis or directly into the lesion (NOT subcutaneous — risk of fat atrophy and depigmentation in surrounding skin).
7. Warn the patient about post-injection flare — up to 5% of patients have a paradoxical 6–48 hour increase in joint pain after IA injection, due to a crystal-induced inflammatory response. Treat with NSAIDs or paracetamol; settles spontaneously.
8. Document: site, dose, vial batch and expiry, technique, complications. Important for joint-injection-frequency limits.
9. NEVER inject into a joint with possible septic arthritis — if the joint is hot, swollen, very painful, the patient is febrile, or the joint history is unclear, aspirate and send fluid for urgent culture FIRST. Triamcinolone into a septic joint is catastrophic.

Repeat Injections and Cumulative Steroid Burden

A single IM depot of 40–80 mg triamcinolone delivers roughly the systemic equivalent of 50–100 mg of prednisolone over the following 3–4 weeks — comparable to a moderate oral course. Patients receiving repeated IM depots (for example, every pollen season) accumulate the same total steroid exposure as a low-dose oral steroid taken continuously.

• Joint injections: max 3–4 injections per joint per year, min 3 months between injections to the same joint. Patients receiving multiple joints should still respect total annual cumulative dose.
• IM depot for allergic rhinitis: single injection per pollen season is the recommended ceiling. Annual repeat is acceptable; multiple injections per season should not be done.
• Patients on regular IM depot develop the same long-term steroid risks as oral users: osteoporosis, cataract, raised glucose, raised BP, and HPA suppression. Bone-density screening and BP/glucose monitoring should be considered for anyone receiving more than 2–3 IM depots per year for several years.
• HPA suppression after a single IM depot can persist for 2–6 weeks — relevant if the patient becomes ill or needs surgery within that window. A steroid card is sensible.

Side Effects of Kenacort Injection

Side effects fall into local (at the injection site) and systemic (from absorbed drug). Local effects are unique to depot injection; systemic effects mirror oral steroid use in proportion to cumulative dose.

Local — common:

• Skin atrophy and hypopigmentation — dimpled, pale, slightly indented skin around the injection site, especially with superficial intralesional injection in dark-skinned patients. Develops over 4–12 weeks; may be permanent.
• Subcutaneous fat atrophy — particularly with IM depot when injection is too superficial. The Z-track technique and deep IM placement reduce risk.
• Post-injection flare — 1–5% of intra-articular injections produce a paradoxical 6–48 hour increase in joint pain. Settles spontaneously; treat with NSAIDs.
• Telangiectasia at the injection site (visible small blood vessels)
• Local sterile abscess (rzadkie)

Local — serious (rare):

• Septic arthritis from joint injection — estimated risk 1 in 10,000 to 1 in 50,000. Presents as severe joint pain, fever, redness 24–72 hours after injection. Surgical emergency.
• Tendon rupture from peri-tendinous injection — weight-bearing tendons (Achilles, patellar) are most at risk; avoid injection directly into tendon body
• Cartilage damage with repeated joint injection — basis of the 3-injection-per-year limit

Systemic — from absorbed drug:

• Transient hyperglycaemia (especially in diabetes) for 1–3 weeks after IM depot
• Facial flushing for 24–48 hours after injection
• Nieregularne miesiączkowanie
• Mood change, insomnia for the first 1–2 weeks
• HPA suppression for 2–6 weeks after a single IM depot
• Cumulative effects (osteoporosis, cataract) with repeated injections over years

Rare but serious — seek urgent review:

• Severe joint pain, fever, redness 24–72 hours after IA injection — septic arthritis until proven otherwise
• Sudden vision change after periorbital injection — possible retinal embolism (very rare with triamcinolone but reported)
• Anaphylaxis to drug or vehicle — the polysorbate or benzyl alcohol in the suspension can cause hypersensitivity

Ostrzeżenia i środki ostrożności

• Active or untreated infection — steroids mask signs of infection and worsen outcomes. Do not use for undiagnosed fever. Established infection sometimes still requires steroid (e.g. severe COVID-19) but specialist judgement only.
• Latent TB — screen before any prolonged or repeated course; consider isoniazid cover if positive.
• Cukrzyca — expect significant worsening; up-titrate oral hypoglycaemics or insulin during the course.
• Hypertension, heart failure — triamcinolone has minimal mineralocorticoid effect, so fluid retention is less than with prednisolone, but BP can still rise via direct vascular effects.
• Peptic ulcer disease, history of GI bleed, NSAID co-prescription — co-prescribe a PPI for any moderate-to-long course.
• Osteoporosis risk — particularly relevant for patients receiving repeated IM depots or long oral courses.
• Glaucoma and cataract — periorbital injection in particular can raise intraocular pressure; annual ophthalmology review for long-term users.
• Psychiatric history — pulse-dose IV and high-dose oral steroid can trigger mania, depression, psychosis. Use the lowest effective dose; warn the patient and family.
• Ciąża — triamcinolone crosses the placenta; considered compatible with pregnancy when indicated for serious maternal disease, but routine elective use should be deferred. IM depot is not advisable in pregnancy because of the long, uncontrollable exposure window.
• Karmienie piersią — small amounts pass into milk; clinically insignificant at typical anti-inflammatory doses. After IV pulse, defer breastfeeding for 4 hours after a 1 g infusion to minimise infant exposure.
• Dzieci — growth suppression is a real concern with prolonged use; monitor height and weight, use minimum effective dose for minimum duration.
• Osoby w podeszłym wieku — higher risk of osteoporosis, diabetes, infection, psychiatric effects. Lower doses and shorter durations when possible.
• Szczepionki żywe — contraindicated at immunosuppressive doses (oral ≥ 16 mg/day triamcinolone or equivalent for 2+ weeks; IM depot acts as continuous immunosuppressive exposure for 4–6 weeks per dose). Inactivated vaccines (flu, pneumococcal, COVID-19, recombinant Shingrix) are fine.
• Anticoagulation — uninterrupted warfarin or DOAC is usually safe for IM and IA injection in stable patients, but discuss with the prescriber if INR is unstable. Use the smallest possible needle and apply firm pressure after withdrawal.

Contraindications — Who Should NOT Receive Kenacort Injection

• Known hypersensitivity to triamcinolone, the vehicle (polysorbate 80, benzyl alcohol), or any related corticosteroid
• Systemic fungal infection (unless specifically covered by antifungal therapy)
• Untreated active bacterial, viral, mycobacterial or parasitic infection without appropriate treatment
• Recent live vaccine administration at immunosuppressive doses
• Cerebral malaria (corticosteroids worsen outcome)
• Septic arthritis or possible septic arthritis — absolute contraindication to intra-articular injection
• Joint instability or unstable fracture at the injection site
• Skin infection at the proposed injection site
• Allergy to the local anaesthetic if combined
• Severe, unstable psychiatric disorder without psychiatric co-management (relative)

Interakcje lekowe

Instrukcja przechowywania

• Przechowywać w temperaturze pokojowej, 15–25°C, protected from light. Do not freeze.
• Shake the vial thoroughly immediately before drawing up — this is a suspension; the active drug settles on standing.
• Once the vial is opened or punctured, use within the labelled in-use period (typically up to 24 hours when refrigerated, depending on local guidance).
• Discard any vial showing visible clumping that does not redisperse on shaking.
• Przechowywać w miejscu niedostępnym dla dzieci.
• Do not use after the expiry date on the pack.
• Return unused product to a pharmacy for disposal — do not flush or discard in household waste.

Powiązane alternatywy w MedsBase

Other medications used in anti-inflammatory and autoimmune care stocked alongside this product:

• Barinat (baricitinib 2 / 4 mg) — JAK1/2 inhibitor for RA
• Tofe (tofacitinib 5 mg) — JAK1/3 inhibitor for RA, UC, PsA
• Azoran (azathioprine 50 mg) — classic immunosuppressant DMARD
• Lefuheal (leflunomide) — oral DMARD for rheumatoid arthritis
• Conimune ME (cyclosporine) — calcineurin inhibitor
• Wysolone (prednisolone 5 / 10 / 20 mg) — oral corticosteroid
• Medrol (methylprednisolone 4 / 8 / 16 mg) — oral corticosteroid
• Predniheal (prednisolone) — oral corticosteroid
• Hisone (hydrocortisone) — physiologic replacement steroid
• Budez CR (budesonide) — gut-targeted corticosteroid for Crohn's
• Kenacort (triamcinolone) — systemic corticosteroid

Explore the full Leki przeciwzapalne i terapia autoimmunologiczna kategorię.

Najczęściej zadawane pytania

How long does a single Kenacort Injection injection last?

For intra-articular injection, useful symptomatic relief usually lasts 4–8 tygodniach, occasionally longer (some patients in osteoarthritis report several months). For IM depot in seasonal allergic rhinitis, the systemic effect lasts 3–6 tygodni. For intralesional injection in keloid scars, individual injections are repeated every 3–6 weeks for several cycles. Effect duration is not strictly proportional to dose — the suspension dissolves at a set rate, so doubling the dose doubles the absorbed dose but does not double the duration.

How often can I have a joint injection of Kenacort Injection?

The widely-accepted limits are maximum 3–4 injections per joint per year, with at least 3 miesiące between injections to the same joint. More frequent use accelerates cartilage degradation and the underlying disease. Different joints can be injected at different times, but cumulative total annual triamcinolone dose should still be respected to avoid systemic steroid burden equivalent to chronic oral therapy.

What is post-injection flare?

About 1–5% of patients have a paradoxical 6–48 hour increase in joint pain after intra-articular triamcinolone — sometimes severe enough to mimic septic arthritis. The cause is a sterile inflammatory response to the microcrystalline drug. It settles spontaneously within 1–2 days. Treat with rest, ice, and oral NSAIDs or paracetamol. If the flare lasts longer than 72 hours, is associated with fever or spreading redness, or seems disproportionate, get same-day medical review — rare but real risk of septic arthritis.

Why does my skin go pale after Kenacort Injection injection?

Triamcinolone can cause local hypopigmentation (lightening of skin tone) and skin atrophy (a slight indentation or thinning) at the injection site. The risk is highest with intralesional or superficial subcutaneous injection, in dark-skinned patients, and with repeated injections to the same area. The change usually develops over weeks to months and may persist for many months or be permanent. Deep IM injection (gluteal, with Z-track technique) and accurate intra-lesional placement reduce but do not eliminate the risk. Tell the prescriber if it happens after a previous injection.

Can I drive after a joint injection?

Yes, if no local anaesthetic is used and you feel fit. If the injection was combined with lidocaine (commonly added to small-joint or peri-tendinous injections), avoid driving for at least 1–2 hours, and arrange a lift if a major weight-bearing joint (knee, ankle) was injected — brief loss of motor control is theoretically possible. Avoid heavy weight-bearing on the injected joint for 24–48 hours to give the suspension time to settle into the joint capsule.

Will the injection raise my blood sugar?

Yes — expect a transient rise in blood glucose for 1–3 weeks after IM depot, and a smaller rise after IA injection. In well-controlled diabetes the rise may be 2–5 mmol/L; in poorly-controlled diabetes it can be much larger. Tell your diabetes team about the injection so insulin or oral agents can be temporarily up-titrated. Most patients do not need a permanent change; the effect resolves as the depot is exhausted.

Can I have an IM Kenacort Injection injection in pregnancy?

IM depot triamcinolone is generally avoided in pregnancy because the long, uncontrollable exposure window cannot be reversed if a problem arises. Short oral steroid courses are preferred when systemic glucocorticoid is needed in pregnancy. Single intra-articular injection for incapacitating joint pain has been used safely in selected cases, but the decision should be made by an obstetrician familiar with the case.

Should I have my IM depot for hay fever every season?

This is debated. A single IM depot of 40–80 mg can be very effective for severe seasonal allergic rhinitis, but it delivers systemic glucocorticoid exposure equivalent to several weeks of oral prednisolone — with all the same risks (osteoporosis, cataract, glucose intolerance, HPA suppression). Modern guidelines (BSACI, EAACI) recommend trying intranasal steroid + oral antihistamine + sublingual immunotherapy first, and reserving IM depot for severe cases unresponsive to those. If repeated annually for many years, bone-density screening is sensible.

When should I worry after an injection?

Seek same-day review if any of the following develops 24–72 hours after injection: severe joint pain disproportionate to the procedure, fever, spreading redness or warmth at the injection site, joint that becomes hot and difficult to move, generalised feeling of being unwell. These can indicate septic arthritis — a surgical emergency. Mild post-injection flare is usually settled within 48 hours; anything worse or longer warrants urgent assessment.

Dlaczego warto zamawiać z MedsBase

Kenacort Injection is supplied through a WHO-GMP certified manufacturer with full COA documentation. We ship worldwide in plain, discreet packaging, and every order is covered by our Reshipment Assurance Policy. Przy płatności kartą w opisie transakcji widnieje nazwa regulowanego procesora płatności (regulowany procesor płatności kartowych), nigdy “MedsBase” ani nazwa leku.

Other Anti-Inflammatory & Autoimmune Medications

If Kenacort Injection does not suit your situation, the following options are available in this category:

• Solu-Medrol (Methylprednisolone IV 40/125/500 mg) — high-dose IV pulse
• Kenacort (Triamcinolone 4 mg) — oral version of the same molecule
• Tricort (Triamcinolone 4 mg, Cipla) — oral triamcinolone
• Wysolone (Prednisolone 5/10/20 mg, Wyeth) — oral corticosteroid
• Medrol (Methylprednisolone 4/8/16 mg, Pfizer) — oral methylprednisolone

More options in Anti Inflammatory & Autoimmune Care

Ranking według liczby ostatnich zamówień MedsBase — co wybierają inni klienci w tej kategorii.

Hisone

US$30.00 – US$235.00Rango de precios: desde US$30.00 hasta US$235.00

Conimune ME

US$45.00 – US$220.00Rango de precios: desde US$45.00 hasta US$220.00

Septilin

US$11.00 – US$41.00Rango de precios: desde US$11.00 hasta US$41.00

Azoran

US$26.00 – US$116.00Rango de precios: desde US$26.00 hasta US$116.00